To validate this hypothesis, we utilized the GDSC database, which includes 18 TNBC cell lines tested for their response to a different MCL1 inhibitor called AZD5991 that entered clinical trials for hematologic cancers. Here, MCL1 is linked to hematopoietic and lymphoid cell neoplasm.